ro's glp-1 supply tracker Taking Stock: What Reveals about the Drug Shortages Ro GLP-1 Supply Tracker

In summary, although both Otelixizumab and Teplizumab show potential in T1D immunotherapy, Teplizumab stands out with FDA approval for T1D prevention and has proven to positively impact cell function while maintaining a manageable safety profile

Unlike diabetes, which is widely accepted as a chronic condition requiring ongoing pharmacologic management, obesity treatment often lacks the same framing, leading to premature discontinuation

Is GLP-1 Tolerance a Real Thing In the clinical pharmacology sense, no strong evidence shows that GLP-1 receptors downregulate from chronic exposure to semaglutide or tirzepatide in humans

One detail that shapes the clinical narrative is that plasma DSIP levels show a diurnal pattern , reported as lower in the morning and higher in the evening